Type I Interferonopathies : A Clinical Review
Copyright © 2023 Elsevier Inc. All rights reserved..
This review will discuss when clinicians should consider evaluating for Type I interferonopathies, review clinical phenotypes and molecular defects of Type I interferonopathies, and discuss current treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Rheumatic diseases clinics of North America - 49(2023), 4 vom: 09. Nov., Seite 741-756 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Christine S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aicardi-goutières syndrome |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 11.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rdc.2023.06.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363142436 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363142436 | ||
| 003 | DE-627 | ||
| 005 | 20231227131731.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.rdc.2023.06.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1226.xml |
| 035 | |a (DE-627)NLM363142436 | ||
| 035 | |a (NLM)37821193 | ||
| 035 | |a (PII)S0889-857X(23)00062-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Christine S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Type I Interferonopathies |b A Clinical Review |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 11.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a This review will discuss when clinicians should consider evaluating for Type I interferonopathies, review clinical phenotypes and molecular defects of Type I interferonopathies, and discuss current treatments | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Aicardi-goutières syndrome | |
| 650 | 4 | |a Inborn errors of immunity | |
| 650 | 4 | |a Interferonopathies | |
| 650 | 4 | |a Monogenic lupus | |
| 650 | 4 | |a Type I interferonopathy | |
| 650 | 7 | |a Interferon Type I |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Rheumatic diseases clinics of North America |d 1988 |g 49(2023), 4 vom: 09. Nov., Seite 741-756 |w (DE-627)NLM012610534 |x 1558-3163 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2023 |g number:4 |g day:09 |g month:11 |g pages:741-756 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rdc.2023.06.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2023 |e 4 |b 09 |c 11 |h 741-756 | ||